A Sri Lankan worker in the exports processing sector gets inoculated against the coronavirus at a vaccination center run by the military in Colombo. (Photo | AP) 
World

Sri Lanka extends nationwide curfew till September 21 to curb COVID-19 spread

Rambukwella said the number of COVID-19 patients in the country was steadily declining and authorities were confident that Sri Lanka would once again be able to reopen without risk.

ANI

COLOMBO: Sri Lankan authorities on Friday further extended a nationwide quarantine curfew till September 21 to prevent further spread of the COVID-19. Health Minister Keheliya Rambukwella said the curfew will be lifted at 4 am on September 21 after a decision made by President Gotabaya Rajapaksa following a meeting with the COVID-19 Task Force.

Rambukwella said the number of COVID-19 patients in the country was steadily declining and authorities were confident that Sri Lanka would once again be able to reopen without risk. "Please adhere to the regulations, use this time to get vaccinated, stay home and wear a mask," the health minister said.

Army Commander General Shavendra Silva said President Rajapaksa had instructed authorities to submit a report as to what type of restrictions should be imposed if the quarantine curfew is lifted after September 21.

Sri Lanka was to lift the ongoing quarantine curfew on September 13 but extended it following a recommendation from health experts. The country is facing a rapid spread of the Delta variant of the virus with 58,656 active patients in the country and 477,636 people contracting the COVID-19 infection since March last year.

Why the additional declaration linked to Form 6 is facing a legal challenge

SP-Congress alliance faces fresh strain as Akhilesh skips INDIA bloc meet over UP seat-sharing talks

Rahul Gandhi tells CWC to continue 'resistance' against 'match-fixing' of polls through EVM, voters list

Assam Rifles jawan killed in militant attack in Arunachal; security forces intensify ops to arrest killers

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’